Apexigen Revenue and Competitors
Estimated Revenue & Valuation
- Apexigen's estimated annual revenue is currently $2.2M per year.
- Apexigen's estimated revenue per employee is $100,500
- Apexigen's total funding is $158M.
Employee Data
- Apexigen has 22 Employees.
- Apexigen grew their employee count by -35% last year.
Apexigen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Operating Officer | Reveal Email/Phone |
2 | SVP, Finance and Operations | Reveal Email/Phone |
3 | SVP CMC | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Chief Medical Officer and SVP, Clinical Development | Reveal Email/Phone |
6 | Senior Director, Program Management | Reveal Email/Phone |
7 | Director CMC Quality | Reveal Email/Phone |
8 | Remote Sr. Clinical Data Manager | Reveal Email/Phone |
9 | Staff Accountant | Reveal Email/Phone |
Apexigen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Apexigen?
Apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by APXiMABￃﾢ￢ﾀﾞￂﾢ, the Companyￃﾢ￢ﾂﾬ￢ﾄﾢs proprietary antibody drug discovery platform. Its lead immuno-oncology drug candidate, APX005M, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.
keywords:Biotechnology
$158M
Total Funding
22
Number of Employees
$2.2M
Revenue (est)
-35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Apexigen News
Apexigen Announces New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Pembrolizumab in Patients...
SAN CARLOS, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Apexigen, ... Apexigen's monoclonal antibody targeting CD40, in combination with...
SAN CARLOS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Apexigen, ... Apexigen's monoclonal antibody targeting CD40, in combination with...
SAN CARLOS, Calif., April 9, 2021 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced two upcoming poster presentations accepted as late breaking abstracts at th ...
SAN CARLOS, Calif., Nov. 9, 2020 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced two upcoming poster presentations at the 35th Society for Immunotherapy of C ...
Other Companies in San Carlos
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.2M | 22 | -4% | N/A |
#2 | $2.5M | 22 | 47% | $20M |
#3 | $5.3M | 23 | 15% | $13M |
#4 | $2.5M | 25 | 9% | N/A |
#5 | $3.6M | 26 | -4% | N/A |